Miao Yunxuan, Chen Yisheng, Lan Qiaofen, Chen Ruogu, Zhuang Jiajia, Shi Haojun, Wang Miao, Miao Jianhui, Lin Chengshou
Henan University of Science and Technology, Luoyang, Henan, China.
Fujian Key Laboratory of Toxicant and Drug Toxicology, Medical College, Ningde Normal University, Ningde, Fujian, China.
Front Pharmacol. 2025 Jul 17;16:1610301. doi: 10.3389/fphar.2025.1610301. eCollection 2025.
She Medicine, a traditional therapeutic system from China's She ethnic group, shows promise in cancer treatment. This paper provides a comprehensive review of She medicinal herbs, focusing on their anticancer activities and underlying mechanisms. Compared to widely studied traditional medicines (e.g., Traditional Chinese Medicine), She Medicine exhibits unique ethnopharmacological traits, such as localized plant usage and multi-target mechanisms involving apoptosis induction, immune modulation, and tumor microenvironment regulation. Key herbs like and showing significant anticancer potential due to their bioactive compounds such as flavonoids, quercetin, and gallic acid. For example, homoharringtonine (HT), a She-derived alkaloid, targets Smad3/TGF-β pathways in non-small cell lung cancer and synergizes with chemotherapy in leukemia treatment, as evidenced by preliminary clinical trials. However, challenges persist, including resource shortages, insufficient mechanistic studies, and a lack of quality control standards. Future research should integrate multi-omics and bioengineering approaches to standardize She Medicine and bridge its traditional use with modern therapies such as immune checkpoint inhibitors. Overall, She medicinal herbs hold great promise for cancer treatment and warrant further exploration to unlock their full potential in modern medicine.
畲医药是中国畲族的一种传统治疗体系，在癌症治疗方面显示出前景。本文对畲药进行了全面综述，重点关注其抗癌活性及潜在机制。与广泛研究的传统药物（如中药）相比，畲医药具有独特的民族药理学特征，如植物的本地化使用以及涉及诱导凋亡、免疫调节和肿瘤微环境调节的多靶点机制。像[未提及具体草药名称]等关键草药因其黄酮类、槲皮素和没食子酸等生物活性化合物而具有显著的抗癌潜力。例如，从畲药中提取的生物碱高三尖杉酯碱（HT），在非小细胞肺癌中靶向Smad3/TGF-β通路，并在白血病治疗中与化疗协同作用，初步临床试验证明了这一点。然而，挑战依然存在，包括资源短缺、机制研究不足以及缺乏质量控制标准。未来的研究应整合多组学和生物工程方法，以规范畲医药，并将其传统用途与免疫检查点抑制剂等现代疗法相衔接。总体而言，畲药在癌症治疗方面具有巨大潜力，值得进一步探索以释放其在现代医学中的全部潜能。
